Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
56.22
+0.55 (+0.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Crispr Therapeutics Ag
< Previous
1
2
...
20
21
22
23
24
25
26
27
Next >
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.
Via
InvestorPlace
7 Best Biotech Stocks to Buy in July 2022
July 08, 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.
Via
InvestorPlace
Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?
July 07, 2022
The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.
Via
Investor's Business Daily
Jim Cramer Says This Company Isn't Making Money
June 24, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is hearing nothing but positives of late about Nokia Corp (NYSE: NOK) over the previous four weeks. "I think it’s right to buy," he added.
Via
Benzinga
Analyst Ratings for CRISPR Therapeutics
June 13, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Evercore ISI Group Downgrades CRISPR Therapeutics: Here's What You Need To Know
June 23, 2022
Evercore ISI Group downgraded its rating of CRISPR Therapeutics (NASDAQ:CRSP) to In-Line with a price target of $60.00, changing its price target from $66.00 to $60.00. Shares of CRISPR Therapeutics...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
June 23, 2022
Upgrades
Via
Benzinga
Why CRISPR Therapeutics Stock Is Falling
June 22, 2022
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading lower Wednesday after several analysts adjusted price targets on the stock following the company's Innovation Day.
Via
Benzinga
Chardan Capital Maintains Buy Rating for CRISPR Therapeutics: Here's What You Need To Know
June 22, 2022
Chardan Capital has decided to maintain its Buy rating of CRISPR Therapeutics (NASDAQ:CRSP) and lower its price target from $168.00 to $164.00. Shares of CRISPR Therapeutics are trading down 8.24% over...
Via
Benzinga
Bear Market Rally Lifts HealthCare Stocks Off Bottom
June 22, 2022
Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma.
Via
Talk Markets
CNBC's Final Trades: Ethereum, Charles Schwab, Clean Energy, Boeing And This Biotech Stock
June 16, 2022
On CNBC’s “Halftime Report Final Trades,” Kevin O'Leary, known as "Mr.
Via
Benzinga
Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?
June 13, 2022
Crispr and Vertex tested their gene-edited drug in two blood diseases.
Via
Investor's Business Daily
93 Biggest Movers From Yesterday
June 14, 2022
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...
Via
Benzinga
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
June 13, 2022
CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic...
Via
Benzinga
70 Stocks Moving In Monday's Mid-Day Session
June 13, 2022
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric...
Via
Benzinga
How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing
June 10, 2022
The company is using a different approach to tackle the blood disease.
Via
Investor's Business Daily
7 No-Brainer Biotech Stocks to Add to Your Buy List
June 09, 2022
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile.
Via
InvestorPlace
7 Oversold Stocks to Buy Right Now
June 08, 2022
Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price.
Via
InvestorPlace
IBD Tech Leader Vertex Snags Upgrade As Non-Cystic Fibrosis Drugs Crystallize
June 01, 2022
One analyst expects multiple new drug launches between 2024-26.
Via
Investor's Business Daily
Cathie Wood Provides Lesson of the Day: Don't Invest in Fairytale Stocks
May 20, 2022
Tesla is no longer the No.1 holding of Cathie Wood's ARK. Let's see what's inside.
Via
Talk Markets
Analyst Ratings for CRISPR Therapeutics
May 17, 2022
Over the past 3 months, 11 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
How to Buy Stocks in a Recession
May 16, 2022
The same strategies for buying stocks during a bull market don't apply during a recession. Learn what you need to do going forward.
Via
InvestorPlace
5 Cathie Wood Stocks to Buy Now
May 16, 2022
ARK Invest funds led by Cathie Wood seek long-term capital growth and focus mainly on disruptive innovation. Here's a look a five related stocks to consider.
Via
InvestorPlace
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
May 12, 2022
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.
Via
Investor's Business Daily
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
May 10, 2022
Via
Benzinga
$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much
May 02, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.5% on an annualized basis producing an average annual return of 25.08%. Currently, CRISPR Therapeutics has a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
April 28, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About CRISPR Therapeutics
April 28, 2022
Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings:
Via
Benzinga
3 Cathie Wood Stocks to Count on in Q2
April 26, 2022
These Cathie Wood Stocks have their risks but offer a massive upside potential ahead, especially if you can handle the volatility.
Via
InvestorPlace
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
< Previous
1
2
...
20
21
22
23
24
25
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.